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Poly(GR) and poly(GA) in cerebrospinal ﬂuid as
potential biomarkers for C9ORF72-ALS/FTD
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Gopinath Krishnan1, Denitza Raitcheva2, Daniel Bartlett2, Mercedes Prudencio3, Diane M. McKenna-Yasek1,
Catherine Douthwright1, Björn E. Oskarsson4, Shafeeq Ladha5, Oliver D. King1, Sami J. Barmada 6,
Timothy M. Miller7, Robert Bowser 5, Jonathan K. Watts 8, Leonard Petrucelli3, Robert H. Brown 1,
Mark W. Kankel9,10 ✉ & Fen-Biao Gao 1 ✉

GGGGCC repeat expansion in C9ORF72, which can be translated in both sense and antisense
directions into ﬁve dipeptide repeat (DPR) proteins, including poly(GP), poly(GR), and
poly(GA), is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD). Here we developed sensitive assays that can detect
poly(GA) and poly(GR) in the cerebrospinal ﬂuid (CSF) of patients with C9ORF72 mutations.
CSF poly(GA) and poly(GR) levels did not correlate with age at disease onset, disease
duration, or rate of decline of ALS Functional Rating Scale, and the average levels of these
DPR proteins were similar in symptomatic and pre-symptomatic patients with C9ORF72
mutations. However, in a patient with C9ORF72-ALS who was treated with antisense oligonucleotide (ASO) targeting the aberrant C9ORF72 transcript, CSF poly(GA) and poly(GR)
levels decreased approximately 50% within 6 weeks, indicating they may serve as sensitive
ﬂuid-based biomarkers in studies directed against the production of GGGGCC repeat RNAs
or DPR proteins.
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F

rontotemporal dementia (FTD) and the motor neuron disease amyotrophic lateral sclerosis (ALS) are regarded as
spectrum disorders whose clinical, pathological, and genetic
characteristics overlap substantially1–3. For instance, the most
common known genetic cause of both diseases is a GGGGCC
(G4C2) repeat expansion in the ﬁrst intron of C9ORF724,5. RNAs
transcribed from these repeats in both sense and antisense
directions can be translated into ﬁve dipeptide repeat (DPR)
proteins—poly(GA), poly(GR), poly(GP), poly(PR), and
poly(PA)6–8. Among them, poly(GR) is likely to be a key neurotoxic species, as its expression strongly correlates with neurodegeneration in the brains of patients with C9ORF72
mutations9–11. Moreover, poly(GR) is toxic in many cellular and
animal models12,13. For example, we established an inducible
mouse model in which (GR)80 is expressed in the brain at
~5–15% of the level in the brains of patients with C9ORF72
mutations and demonstrated that low-level poly(GR) expression
alone can elicit several FTD/ALS-like behavioural and cellular
phenotypes14. Poly(GA), the most abundantly expressed DPR
protein in patients15,16, is likely to be another pathogenic DPR
protein, as mouse models of poly(GA) toxicity exhibited behavioural deﬁcits, neuronal cell loss, and TDP-43 pathology17,18.
Similarly, poly(GA) expression in primary neurons or
HEK293T cells induces the aggregate formation and cellular
toxicity19,20 and disease-related TDP-43 cleavage21.
Although not overly toxic in cellular and animal models,
poly(GP) is widespread in patient brains with C9ORF72 mutations and detectable in their cerebrospinal ﬂuid (CSF), but the
levels do not correlate with disease onset or clinical scores and
stay relatively constant over time22–24. To date, it is unknown
whether other DPR proteins such as poly(GA) and poly(GR) can
also be detected in CSF from patients with C9ORF72 mutations
and if so, whether the levels correlate with any clinical features of
patients. Although poly(GR) and poly(GA) are neurotoxic in
cellular and animal models, it is not known whether these DPR
proteins can serve as diagnostic or target engagement biomarkers
in clinical trials.
One promising therapeutic approach for C9ORF72-ALS/FTD
is to use antisense oligonucleotides (ASOs) to reduce the
expression of G4C2 repeat-containing RNAs. ASOs have been
used successfully to alter splicing patterns in spinal muscular
atrophy (SMA) and hold great promise for treating other neurodegenerative diseases25. Indeed, an ASO targeting the ﬁrst
intron of C9ORF72 has been given to a single patient with ALS26.
Another potential therapeutic approach is antibodies against
speciﬁc DPR proteins. In a study of C9ORF72 human BAC
transgenic mice, targeting poly(GA) proteins with an antibody
reduced poly(GA) aggregates and increased survival, improved
behaviour, and rescued neurodegeneration27. Additionally, active
poly(GA) vaccination prevents microglia activation and motor
deﬁcits in mice overexpressing poly(GA)28. For these and other
therapies targeting G4C2 repeat RNAs or DPR proteins, it is
essential to develop assays to detect poly(GA) and poly(GR) in
human ﬂuids. Here we describe our efforts to establish poly(GA)
and poly(GR) in CSF as sensitive biomarkers of C9ORF72ALS/FTD.
Results
Poly(GR) is a CSF biomarker speciﬁc for patients with
C9ORF72-related ALS/FTD. We previously established a Meso
Scale Discovery (MSD)-based assay to measure poly(GR) expression in transgenic mice and ﬂies as well as in human neurons
differentiated from induced pluripotent stem cell (iPSC) lines of
patients with C9ORF72 mutations14,29,30. MSD immunoassay is a
2

highly sensitive method that uses electrochemiluminescence (ECL)
to detect protein levels, in contrast to the less sensitive colorimetric
reaction used in traditional enzyme-linked immunosorbent assays
(ELISAs)31. To establish that our MSD immunoassay can detect
poly(GR) in CSF from patients with C9ORF72 mutations, we ﬁrst
performed spike-and-recovery experiments in which synthetic
(GR)8 peptide was added to CSF samples from healthy people at
concentrations of 1.56–25 pg/ml; the recovery rate was 75–92%
across ﬁve different concentrations (Fig. 1a). The standard curve of
(GR)8 peptide was 1.56–100 pg/ml; 3 pg/ml was the lower limit of
quantiﬁcation (LLOQ) (Fig. 1b). The coefﬁcient of variance (CV)
was 0.67–12.81% for intraplate replicates, 1.54–15.01% for interplate replicates, and 1.89–20.69% for day‐to‐day replicates (Fig. 1c).
Assays with a CV < 20% are considered reliable by the US Food and
Drug Administration32. To demonstrate the clinical utility of the
assay as recommended33, we used CSF samples from three patients
with C9ORF72 mutations. The intra-assay CV was 1.35–0.50% and
the inter-assay CV was 7.67–16.24% (Supplementary Fig. 1a). CSF
samples from 25 patients with C9ORF72 mutations measured in
duplicate well in a single experiment have an intra-assay CV
between 0.15 and 20.35%. (Supplementary Fig 1b). Thus, the assay
meets acceptable quality control statistical standards. Next, we did a
dilution linearity test using two patient samples spiked with 200 ng/
ml of (GR)8 peptide. The dose-response was linear (with R square
values of 0.987 and 0.997) within the range of the standard curve
(Fig. 1d). Finally, we assessed GR immunoassay selectivity by
testing up to 100 ng/ml (GP)8 and (GA)8 peptides spiked in control
CSF samples. We found no signiﬁcant signal, suggesting that the
assay speciﬁcally detects (GR)8 (Fig. 1e).
To further demonstrate that we can reliably measure poly(GR)
in a blinded manner, we used our MSD assay to examine CSF
samples from two independent cohorts, one consisting of four
healthy and four samples from patients with C9ORF72 mutations
and the other consisting of three samples from healthy
participants and ﬁve samples from patients with C9ORF72
mutations. In healthy CSF samples, poly(GR) was not detected,
whereas a clear signal above the background was observed for
poly(GR) in the C9ORF72 CSF samples (Fig. 1f, g). Similar results
were obtained with CSF samples from a third, larger cohort of
CSF samples from 19 healthy participants, 19 patients with ALS
but without C9ORF72 mutations, and 10 patients with C9ORF72ALS from the NEALS Consortium (Fig. 1h). None of the CSF
samples from the NEALS Consortium was excluded due to a low
poly(GR) signal in our assay. Thus, our results show that
poly(GR) is detectable in CSF and is a potentially valid ﬂuidbased biomarker for C9ORF72-ALS/FTD.
Poly(GR) and poly(GA) levels in CSF do not correlate with
clinical features of patients with C9ORF72 mutations. Since
poly(GR) expression in patient brains with C9ORF72 mutations
correlates with neurodegeneration and clinical phenotypes9–11,
we examined whether poly(GR) levels in CSF samples of patients
with C9ORF72-related ALS and ALS/FTD correlate with clinical
features. For this analysis, we used a combined set of CSF samples
from the C9ORF72 Natural History and Biomarkers Study (PMID
31578300) and the NIH Intramural study NCT01925196 (Biogen
cohort). The Revised Amyotrophic Lateral Sclerosis Functional
Rating Scale (ALSFRS-R) scores and age of onset and duration of
disease were available for all patients with C9ORF72 mutations
for whose CSF samples were used here; the samples were further
classiﬁed according to whether the patients were symptomatic or
pre-symptomatic. We obtained 41 CSF samples from symptomatic patients with C9ORF72 mutations and 14 CSF samples
from pre-symptomatic C9ORF72 carriers. In samples from
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Fig. 1 Blinded measurement of poly(GR) levels in CSF in multiple cohorts of patients with C9ORF72 mutations using the MSD-based poly(GR)
immunoassay. a In spike-and-recovery experiments, recombinant (GR)8 peptide was added to CSF from healthy individuals and subsequently serially
diluted into a separate tube containing CSF from healthy individuals to create a 5-point series. The average recovery rate in two different samples was
81–88%. b The assay can detect puriﬁed (GR)8 peptide at concentrations as low as 3 pg/ml. Replicates of 8-point series standard curve run on different
dates are shown. A four-parameter logistic curve was used to ﬁt the dose-response with GraphPad Prism 9.1. c Across the dynamic range of the assay, the
coefﬁcient of variation is less than 16% for all points except one concentration (100 pg/ml), below the 20% cutoff recommended by the FDA in standard
variability for liquid-binding assays. d Dilution linearity was evaluated by measuring duplicates of 5 dilutions of 2 patient CSF samples spiked with 200 ng/
ml (GR)8 peptide. e Poly(GR) immunoassay speciﬁcally detects (GR)8 peptide in control CSF and did not cross react with even up to 100 ng of (GP)8
peptide in control CSF, n = 3 independent experiments, values are mean ± s.e.m. f CSF samples from 4 healthy and 4 patients with C9ORF72 mutations
from the Mayo Clinic, Florida, values are mean ± s.e.m (p = 0.0017, Unpaired t-test with Welch’s correction). g CSF samples from 3 healthy people from
the NEALS cohort and 5 CSF samples from two patients with C9ORF72 mutations from the Barrow Institute, Arizona, values are mean ± s.e.m (p = 0.0012,
Unpaired t-test with Welch’s correction). h 19 healthy people, 19 patients with ALS but without C9ORF72 mutations (3 patients with duplicate samples, 16
patients with single samples), and 10 patients with C9ORF72 mutations (8 patients with duplicate samples, 2 patients with single samples) from the NEALS
Consortium. Values from duplicate samples are presented as mean ± s.e.m (p = 0.9460 control vs non-C9-ALS, p < 0.0001 non-C9-ALS vs C9-ALS,
p < 0.0001 control vs C9-ALS Ordinary one-way ANOVA-Tukey’s multiple comparisons test). Source data are provided as a Source Data ﬁle.

25 symptomatic patients that had poly(GR) levels within the
linear range, poly(GR) levels in CSF did not correlate signiﬁcantly
with ALSFRS-R scores (Supplementary Fig. 2a) or the rate of
ALSFRS-R score decline (Fig. 2a). Nor did poly(GR) levels in CSF
correlate with the age of onset (Fig. 2b) or duration of disease
(Fig. 2c). Moreover, CSF samples from 10 pre-symptomatic
patients with C9ORF72 mutations had poly(GR) levels within the
linear range and did not differ signiﬁcantly from the levels in

samples from symptomatic patients (Fig. 2d). Additional CSF
samples especially from pre-symptomatic patients are needed to
further conﬁrm this result. Similar analyses of a subset of patient
samples from this combined cohort with detectable poly(GA)
levels within the linear range of our (GA)60 standard curve also
showed no correlation between CSF poly(GA) and ALSFRS-R
scores (Supplementary Fig. 2b), the rate of ALSFRS-R score
decline (Fig. 3a), age of onset (Fig. 3b), or disease duration
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Fig. 2 Poly(GR) levels in CSF do not correlate with clinical features of patients with C9ORF72 mutations. a–c Correlations between poly(GR) levels and
rate of ALSFRS-R score decline (a), age at disease onset (b), and disease duration (c), determined by two-tailed, Spearman’s rank-correlation analysis.
d Poly(GR) levels in CSF of symptomatic and asymptomatic patients with C9ORF72 mutations are similar (p = 0.114 by two-tailed unpaired t-test with
Mann–Whitney test). Poly(GR) concentrations are presented as values equivalent to (GR)8 peptide and not as an absolute poly(GR) concentration since the
size of poly(GR) in CSF is unknown. 25 out of 41 symptomatic CSF samples and 10 out of 14 pre-symptomatic CSF samples had poly(GR) levels within the
linear range of our standard curves and are presented here. ALS Functional Rating Scale revised (ALSFRS-R). Source data are provided as a Source Data ﬁle.

(Fig. 3c). The samples assessed in Figs. 2, 3 are overlapping but
not identical and include 17 samples in which both GA and GR
were detected. Finally, CSF poly(GA) levels in CSF did not differ
between symptomatic and pre-symptomatic patients (Fig. 3d).
Poly(GR) and poly(GA) in CSF may serve as biomarkers for
ASO treatment in patients with C9ORF72 mutations. To
determine whether poly(GR) or poly(GA) may serve as a
potential target engagement biomarker, we must ﬁrst understand
whether their CSF levels change or remain constant over time.
We found that CSF poly(GR) levels in longitudinal samples from
two symptomatic and two asymptomatic patients with C9ORF72
mutations were stable over 18–54 months (Fig. 4a). This ﬁnding
was conﬁrmed for both poly(GR) and poly(GA) in a second,
larger cohort (Fig. 4b, c).
Next, we assessed whether changes in poly(GR) and poly(GA)
CSF levels could be detected in a patient with C9ORF72-ALS who
was treated with an ASO targeting the sense strand of the ﬁrst
intron of C9ORF72 in a recently published clinical trial26.
Longitudinal CSF samples were obtained at multiple time points
after ASO treatment26. Six weeks after the ﬁrst ASO treatment, we
found that poly(GP) CSF levels decreased only by about 10%,
whereas poly(GR) and poly(GA) CSF levels decreased by 40–50%,
suggesting a substantially faster initial kinetics of decline at least
in this patient with C9ORF72-ALS (Fig. 4d). Moreover, within
36 weeks after multiple ASO treatments, the CSF levels of all
three DPR proteins decreased to comparable levels at or below
20% of original levels (Fig. 4d). Thus, if conﬁrmed in additional
4

patients with C9ORF72-ALS/FTD, poly(GR) and poly(GA) may
be better target engagement biomarkers than poly(GP) because of
their more rapid kinetics of decline.
Discussion
As G4C2 repeat expansion in C9ORF72 is the most common
genetic cause of both ALS and FTD, signiﬁcant effort is ongoing
to develop therapies to reduce repeat-containing RNAs and their
translation products such as poly(GA). Given the emphasis of
these approaches for clinical trials, the ability to measure target
engagement is necessary to properly evaluate the results of these
trials. Thus, we determined whether poly(GA) and poly(GR) can
be detected in patient CSF by MSD-based assays and whether
CSF poly(GA) and poly(GR) levels correlate with clinical measures and could therefore serve as biomarkers of therapeutic
efﬁcacy. Finally, we assessed CSF poly(GA) and poly(GR) levels
for their ability to be used as potential biomarkers. We found that
neither poly(GA) nor poly(GR) in CSF correlated with clinical
measures, suggesting that their levels in CSF may not be useful for
assessing disease severity or therapeutic efﬁcacy. However, the
CSF levels of both DPR proteins decreased rapidly in a single
patient with C9ORF72-ALS treated with an ASO targeting the
intron-containing G4C2 repeats. If conﬁrmed in additional
patients, poly(GR) and poly(GA) may serve as biomarkers of
target engagement.
The lack of correlation between the level of poly(GA)/poly(GR)
and clinical features of patients with C9ORF72 mutations mirrors
what was reported for poly(GP), another DPR protein detectable
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Fig. 3 Poly(GA) levels in CSF do not correlate with clinical features of patients with C9ORF72 mutations. a–c Correlation between poly(GA) levels
and the rate of ALSFRS-R score decline (a), age at disease onset (b), and disease duration (c), determined by two-tailed Spearman’s rank-correlation
analysis. d Poly(GA) levels in CSF from symptomatic and asymptomatic patients with C9ORF72 mutations are similar by two-tailed unpaired t-test with
Mann–Whitney test. Poly(GA) concentrations are presented as values equivalent to (GA)60 and not as an absolute poly(GA) concentration since the size
of poly(GA) in CSF is unknown. The samples assessed in Figs. 2, 3 are overlapping but not identical and include 17 samples for which both poly(GA) and
poly(GR) were detected. Source data are provided as a Source Data ﬁle.

in CSF whose levels do not correlate with disease onset or
clinical scores and stay relatively constant during disease
progression22–24,34–36. Together, these results do not rule out the
possibility that DPR proteins are important in the pathogenesis of
C9ORF72-related diseases, since the dynamic relationship
between DPR protein levels in speciﬁc vulnerable neurons and in
CSF is not well established. Moreover, additional studies are
needed to investigate post-translational modiﬁcations of DPR
proteins (e.g. methylation) and their effects on their neurotoxicity
and detections in CSF samples.
Poly(GP) is currently used as a target engagement biomarker
for C9ORF72 therapies targeting G4C2-repeat-containing transcripts because it is expressed in patient brains with C9ORF72
mutations, is present in patient CSF, and correlates with levels
of repeat-containing RNA in the cerebellum of C9ORF72
carriers22–24,34–36. Our ﬁndings show that poly(GA) and
poly(GR) could also potentially serve as target engagement biomarkers, as their levels remain relatively constant over time and
appear to respond more quickly to ASO therapy than poly(GP).
We attribute the slow decrease in CSF poly(GP) to its expression
from both sense and antisense repeat RNAs and widespread
accumulation due to its demonstrated lack of neuronal toxicity in
the brain.
Our study has some limitations that are worth discussing. First,
several CSF samples from the Biogen cohort exhibited poly(GR)
or poly(GA) signals outside the linear range of our standard
curves and therefore could not be included in our analyses
described here. In contrast, we were able to measure poly(GR)
levels for all of the NEALS cohort CSF samples. Given this
observation, we speculate that there are likely to be unknown
factors that contribute to CSF DPR protein levels and may

therefore account for these differences. For instance, it is possible
that the collection, processing and storage of the CSF samples is a
key aspect to sample integrity and that different clinical sites have
slightly modiﬁed protocols that may affect sample quality (e.g. the
length of collection time, the person collecting samples, collection
vessels, time, and site of puncture, etc.). Consistent with this
notion, others have shown that variations in sample handling can
affect the measurable levels of prion protein in the CSF37.
Nevertheless, given that detectable levels of both poly(GA) and
poly(GR) were observed in a majority of cases, in addition to
further improvement of assay sensitivity, one way to overcome
this limitation in a clinical trial setting is to ﬁrst ensure the quality
of CSF samples and then pre-screen trial participants based on
detectable CSF DPR protein load prior to enrollment. With such
patient selection criteria used in trial designs, appropriate
assessment of candidate therapeutics will become more robust.
Second, we only managed to get access to small numbers of CSF
samples for some analyses; for instance, the number of presymptomatic CSF samples is relatively low, and longitudinal CSF
samples were available only from a single patient with C9ORF72ALS after compassionate use of experimental ASO treatment26.
The faster decrease of CSF poly(GA) and poly(GR) levels than of
the poly(GP) level needs to be conﬁrmed in additional patients
with C9ORF72 mutations after ASO treatment. However, our
ﬁndings that poly(GA) and poly(GR) can be detected in good
quality CSF samples and that their levels decrease in response to
ASO treatment suggest the potential for these DPR proteins to
serve as sensitive target engagement biomarkers in the development of C9ORF72-directed therapies. For instance, these biomarkers could be used to assess correlations between improved
clinical features and loss of DPR proteins, and in prolonged
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Fig. 4 ASO treatment in a patient with C9ORF72-ALS decreases CSF DPR levels. a Poly(GR) levels in CSF were generally stable over time in two
symptomatic and two asymptomatic patients with C9ORF72 mutations. b Longitudinal trend of poly(GR) levels in CSF from a larger cohort of patients with
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time point value for symptomatic patient 2 in panel a and the last time point for poly(GR) value in panel b were above background but below the lower limit
of detection and were not included. Source data are provided as a Source Data ﬁle.

clinical trials, they could be used to show that when a lack of
efﬁcacy or a negative outcome occurs, it is not due to the lack of
target engagement.
Methods
CSF samples. Research complies with all relevant ethical regulations; Patients gave
written informed consent for sharing de-identiﬁed biospecimens under protocols
reviewed by the NIH Institutional review board (NCT01925196), Massachusetts
General Hospital (2015P002295, 2015P002034, 2011P000511, and 2007P002586/1),
UMass Chan Medical School (IRB docket #14341 and #H00004956), Mayo Clinic
Jacksonville (13-004314), St. Joseph’s Hospital, and Medical Center
(IRB#11BN125). ASO treatment of a patient with C9ORF72-ALS was performed at
UMass Chan Medical School (IRB docket #14341 and #H00004956). Coded CSF
samples from healthy people and patients with C9ORF72 mutations were obtained
from multiple institutions including some previously published samples22,24,38.
Requests for these samples should be addressed to these sources. The clinical features of the patients are summarized in Supplementary Tables 1 and 2. The rate of
decline of ALSFRS-R scores was calculated as 48 minus ALSFRS-R score at sampling divided by disease duration in months.
Poly(GR) immunoassay of CSF samples. Poly(GR) levels in CSF samples from
healthy people and patients with C9ORF72 mutations were measured in a blinded
manner, with custom-made, afﬁnity-puriﬁed rabbit polyclonal GR antibodies
raised against (GR)8 peptide and a Meso Scale Discovery platform that uses electrochemiluminescence detection technology as described14 with minor modiﬁcations. In brief, biotinylated poly(GR) antibodies were diluted in phosphate-buffered
saline (PBS) at a concentration of 0.5 μg/ml and coated on 96-well single-spot
streptavidin plates (MSD Gold) and incubated overnight at 4 °C. The next day,
antibodies were removed, washed three times with Tris-buffered saline (TBS)Tween20 (0.05%) wash buffer, and blocked with 1% BSA-TBS-Tween20 (0.05%)
blocking solution or MSD Blocker A solution for 1 h. CSF samples (150–200 μl)
were concentrated with Amicon Ultra 0.5 ml 3 kDa ﬁlters by centrifugation at
14,000 × g for 15 min at room temperature. After 3 kDa ﬁlter centrifugation, very
small dipeptides may ﬂow through the column but we do not expect that pathological poly(GR) proteins are smaller than 3 kDa. Concentrated CSF samples
6

(45 μl) were loaded in duplicate wells and incubated for 1.5 h on a shaking platform. After three washes, plates were loaded with MSD-Gold-Sulfo-tagged
poly(GR) detection antibody (0.5 μg/ml), incubated for 1 h at room temperature on
a shaking platform, and washed three times. MSD-Read buffer (1×) was added, and
the plates were immediately read with an MSD-QuickPlex SQ 120 Reader. After
background correction, sample electrochemiluminescence (ECL) signals were
interpolated against a standard curve prepared with serial dilutions of recombinant
(GR)8 peptide and presented as relative concentration. The lower limit of detection
was calculated using the mean of the background plus 2.5 times the standard
deviation. The sizes of DPR proteins in CSF are unknown; we measured the
amount of total poly(GR) and poly(GA) equivalent to the epitopes detected in
(GR)8 and (GA)60 based on standard curves.

Poly(GA) immunoassay analysis for CSF samples. Poly(GA) levels in C9ORF72
derived patient CSF were measured with a sandwich immunoassay assay that
utilizes the same antibody combinations used to detect poly(GA) levels in several
prior publications27,30,39,40 and the MSD ultrasensitive S-PLEX platform. The MSD
S-PLEX assay utilizes a modiﬁed version of the standard MSD assay protocol,
which includes an alternate detection antibody label, TURBO-BOOST and an
enhancement step featuring a TURBO-TAG label to boost ECL signal and improve
assay sensitivity. Brieﬂy, undiluted CSF was tested for poly(GA) by using human/
murine chimeric forms of capture and detection antibodies as described27; however, the detection antibody was further modiﬁed with a TURBO-BOOST conjugation. Each sample was tested in duplicate wells, sample volume permitting,
using 25 µl per well in MSD S-PLEX 96-well SECTOR plates. The 8-point calibration curve was prepared by serially diluting (GA)60 protein expressed in HEK
293 cells, and four QC samples were included on each assay plate. Electrochemical
stimulation of the assay plate with the MESO® SECTOR S 600 instrument generates ECL signal values that correspond to the intensity of emitted light. The ECL
signal level is proportional to the amount of poly(GA) in the sample, and the
concentrations in CSF samples were interpolated from the calibration curve.

Statistics. Nonparametric Spearman’s rank-correlation tests were used for all
correlation analyses. Nonparametric unpaired t-tests and Mann–Whitney tests
were used to compare samples from symptomatic vs. asymptomatic patients.
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Statistical analyses of poly(GR) and poly(GA) were done with Prism v9.1 and
Prism v7.02., respectively.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All the data presented in this study are included in the Source Data File. Requests for
patient CSF samples should be addressed to the respective institutions.

Code availability
Not applicable.
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